Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness (Q37827219)

23 August 2017

1 reference

title

Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness (English)

1 reference

23 August 2017

1 reference

Martin A Katzman

1

1 reference

23 August 2017

language of work or name

1 reference

1 January 2011

1 reference

Journal of Affective Disorders

23 August 2017

published in

1 reference

23 August 2017

volume

128 Suppl 1

1 reference

23 August 2017

page(s)

S11-20

1 reference

Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Atypical antipsychotic induced weight gain: pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole augmentation in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Treatment-resistant anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Stimulation of hippocampal 5-HT1A receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Divalproex in posttraumatic stress disorder: an open-label clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Panic and panic disorder in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Diagnosis and definition of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open-label pilot study of divalproex sodium for posttraumatic stress disorder related to childhood abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole: profile on efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole as an adjunctive treatment for refractory unipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

What is the genetic relationship between anxiety and depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The nosologic relationship between generalized anxiety disorder and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Adjunctive aripiprazole in treatment-resistant bipolar depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Anticonvulsants in anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Dopamine partial agonists: a new class of antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Treating bipolar disorder in the primary care setting: the role of aripiprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open study of aripiprazole and escitalopram for psychotic major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

1 reference

7 January 2021

Aripiprazole for the maintenance treatment of bipolar I disorder: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole augmentation for treatment of patients with inadequate antidepressants response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Valproate therapy for chronic, combat-induced posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Valproic acid and panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Treatment for mood and anxiety disorders: quetiapine and aripiprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Adjunctive aripiprazole in bipolar I depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Cost of anxiety disorders: impact of comorbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Generalised anxiety disorder: treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Carbamazepine in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Medication augmentation after the failure of SSRIs for depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Posttraumatic stress disorder in vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole acts as a selective dopamine D2 receptor partial agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Phenomenology and course of generalised anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2811%2970004-0

7 January 2021

10.1016/S0165-0327(11)70004-0

Identifiers

DOI

1 reference

23 August 2017

1 reference